NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their RightsApril 27, 2026
Share Twitter Facebook LinkedIn Email Stellantis said Friday it expects to take a roughly 22-billion-euro ($26 billion) as it overhauls its business to accelerate the rollout of electric and hybrid vehicles.Read More